skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

The Medicines Company to Be Acquired by Novartis in $9.7 Billion Deal

Paul, Weiss is advising The Medicines Company in its all-cash $9.7 billion acquisition by Swiss pharmaceutical giant Novartis AG. Under the terms of the agreement, Novartis agreed to pay $85 per share, representing a 45 percent premium to its unaffected share price and a 57 percent premium to its unaffected one-week average price.

The Paul, Weiss team includes corporate partners Scott Barshay, Jeffrey Marell, Justin Rosenberg, Manuel Frey and John Kennedy and counsel Patricia Vaz de Almeida; employee benefits partner Jean McLoughlin; litigation partners Andrew Forman and Rick Rule; intellectual property partner Chuck Googe; real estate partner Peter Fisch; tax partner Jeffrey Samuels; international trade counsel Richard Elliott; antitrust counsel Marta Kelly; and environmental counsel William O’Brien.

November 24, 2019

© 2021 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy